Depósito Académico >
Facultad de Ciencias >
Departamento de Histología y Anatomía Patológica >
DA - Ciencias - HAP - Artículos de revista >
|Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo|
|Authors: ||Hsu, Y.F. (Y. F.)|
Ajona, D. (Daniel)
Corrales, L. (Leticia)
Lopez-Picazo, J.M. (José M.)
Gurpide, A. (Alfonso)
Montuenga, L.M. (Luis M.)
Pio, R. (Rubén)
|Keywords: ||Tumor markers|
Complement factor H
|Issue Date: ||Jun-2010|
|Publisher: ||Biomed Central|
|Publisher version: ||http://dx.doi.org/10.1186/1476-4598-9-139|
|Citation: ||Hsu YF, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010 Jun 7;9:139.|
Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), increases survival in patients with advanced EGFR-positive non-small cell lung cancer when administrated in combination with chemotherapy. In this study, we investigated the role of complement activation in the antitumor mechanism of this therapeutic drug.
EGFR-expressing lung cancer cell lines were able to bind cetuximab and initiate complement activation by the classical pathway, irrespective of the mutational status of EGFR. This activation led to deposition of complement components and increase in complement-mediated cell death. The influence of complement activation on the activity of cetuximab in vivo was evaluated in xenografts of A549 lung cancer cells on nude mice. A549 cells express wild-type EGFR and have a KRAS mutation. Cetuximab activity against A549 xenografts was highly dependent on complement activation, since complement depletion completely abrogated the antitumor efficacy of cetuximab. Moreover, cetuximab activity was significantly higher on A549 cells in which a complement inhibitor, factor H, was genetically downregulated.
We demonstrate for the first time that the in vivo antitumor activity of cetuximab can be associated with a complement-mediated immune response. These results may have important implications for the development of new cetuximab-based therapeutic strategies and for the identification of markers that predict clinical response.
|Permanent link: ||http://hdl.handle.net/10171/13051|
|Appears in Collections:||DA - CIMA - Oncología - Biomarcadores - Artículos de Revista|
DA - Ciencias - HAP - Artículos de revista
|Files in This Item:|
| View / Open |
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.